MOLN

MOLECULAR PARTNERS AG

• TipRanks·05/16 14:40

  Analysts Are Bullish on Top Healthcare Stocks: Molecular Partners (MOLN), Enliven Therapeutics (ELVN)

• TipRanks·05/12 23:15

  Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged

• Seeking Alpha·05/12 20:57

  Molecular Partners GAAP EPS of -$0.67 misses by $0.25

• TipRanks·05/12 20:35

  Molecular Partners Advances Radio-DARPin and Immuno-Oncology Pipeline on Solid Financial Footing in Q1 2026

• PUBT·05/12 20:12

  Molecular Partners Q1 FY26 net loss narrows to CHF 13.14 million

• Benzinga·05/12 20:04

  Molecular Partners Q1 EPS $(0.45) Misses $(0.38) Estimate

• PUBT·05/12 20:00

  Molecular Partners starts Phase 1/2a trial of DLL3-targeting radiotherapy MP0712

• Benzinga·05/12 11:11

  Earnings Scheduled For May 12, 2026

• PUBT·05/04 05:00

  Molecular Partners presents MP0712 data at upcoming scientific conferences

• TipRanks·05/01 11:32

  Molecular Partners publishes MP0317 clinical data in Nature Cancer

• Benzinga·05/01 11:08

  Molecular Partners Announces Publication Of Phase 1 Clinical Data In 'Nature Cancer' That Illustrate The Potential Of Tumor-Localized CD40 Agonist, MP0317, To Modulate The Tumor Microenvironment

• Reuters·05/01 11:00

  MOLECULAR PARTNERS AG - MP0317 SHOWED FAVORABLE SAFETY UP TO HIGHEST DOSE AND SUITABILITY FOR WEEKLY OR THREE-WEEK DOSING

• Reuters·05/01 11:00

  MOLECULAR PARTNERS PUBLISHES PHASE 1 MP0317 DATA IN NATURE CANCER DEMONSTRATING TUMOR-LOCALIZED CD40 ACTIVATION AND TUMOR MICROENVIRONMENT REMODELING

• PUBT·05/01 11:00

  Molecular Partners publishes Phase 1 MP0317 data showing tumor-localized CD40 activation

• Benzinga·04/22 11:51

  HC Wainwright & Co. Reiterates Buy on Molecular Partners, Maintains $13 Price Target